Rapid Micro Biosystems, Inc. Class A (RPID)

In November 2025, RPID reported its third-quarter results, showing revenue growth and raised full-year guidance. In January 2026, the company announced preliminary fourth-quarter and full-year 2025 revenue, expecting significant growth. In March 2026, RPID reported record fourth-quarter and full-year 2025 results, confirming preliminary figures and providing 2026 guidance, and announced follow-on orders from Samsung Biologics and Amgen. In April 2026, Wall Street Zen upgraded RPID to "Hold." As of May 7, 2026, the stock price was $2.57, and the company is scheduled to release its first-quarter 2026 financial results on May 13, 2026.

While a "Seasonality Score: -14" has been noted, specific details regarding the nature of demand seasonality for Rapid Micro Biosystems' products and services are not extensively disclosed. The company's revenue model suggests a degree of stability, but the impact of factors like pharmaceutical manufacturing cycles on the timing of system purchases or consumable demand is not explicitly detailed.

Rapid Micro Biosystems, Inc. (RPID) is a life sciences technology company specializing in automating microbial quality control (MQC) testing for pharmaceutical and biopharmaceutical manufacturing. Their flagship product, the Growth Direct® system, automates traditional MQC testing workflows, providing faster results, greater accuracy, and improved compliance. The company generates revenue from the sale of Growth Direct systems, related software, proprietary consumables, and services.

Rapid Micro Biosystems is headquartered in Lexington, Massachusetts, with U.S. manufacturing operations in Lowell, Massachusetts. Globally, the company has locations in Switzerland, Germany, and the Netherlands. Its Growth Direct systems are used in pharmaceutical manufacturing operations worldwide, with products and services provided in the United States, Switzerland, Germany, Japan, and internationally.

Rapid Micro Biosystems generally maintains a positive brand reputation as a trusted partner in quality control microbiology automation. However, a report in March 2026 indicated potential ESG-related risks that could affect its reputation and operational practices.

Rapid Micro Biosystems has a diverse ownership structure, with institutional investors holding approximately 61.79% of the company, individuals holding about 5.82%, private equity firms owning 43%, and the general public holding a 38% stake. Bain Capital Life Sciences Investors, LLC is the largest holder. The company's CEO, Robert Spignesi, directly holds 1.1% of the total shares outstanding. Recent insider trading activity shows sales by several executives and Longitude Capital Management Co., LLC.